Future studies integrating in vivo validation will therefore be critical to confirming the efficacy and safety of PDGFRβ-targeted strategies in high-PTMRS CRC, and thereby supporting their clinical translation. This evidence concerns the gene PDGFRB and colorectal carcinoma.